Overview

This trial is active, not recruiting.

Condition lymphoma
Treatment rituximab
Phase phase 3
Target CD20
Sponsor Eastern Cooperative Oncology Group
Collaborator National Cancer Institute (NCI)
Start date November 2003
End date September 2013
Trial size 389 participants
Trial identifier NCT00075946, CDR0000346359, ECOG-E4402, U10CA021115

Summary

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known which rituximab regimen is more effective in treating indolent non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying two different schedules of rituximab and comparing them to see how well they work in treating patients with low tumor burden indolent stage III non-Hodgkin's lymphoma or stage IV non-Hodgkin's lymphoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Primary purpose treatment
Arm
(Active Comparator)
Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
rituximab
Given IV
(Experimental)
Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.
rituximab
Given IV

Primary Outcomes

Measure
Time to treatment failure
time frame:

Secondary Outcomes

Measure
Time to first cytotoxic therapy
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed non-Hodgkin's lymphoma, including 1 of the following: - Follicular grade 1 or 2 - Small lymphocytic - Marginal zone (nodal) - Marginal zone (splenic) - Mucosa-associated lymphoid tissue (MALT) - No evidence of transformation to a large cell histology - Stage III or IV disease - Must meet the following criteria for low tumor burden: - No nodal or extranodal mass at least 7 cm - Less than 3 nodal masses greater than 3 cm in diameter - No systemic symptoms or B symptoms - No splenomegaly greater than 16 cm by CT scan - No evidence of risk of compression of a vital organ (i.e., ureteral or epidural) - No leukemic phase with greater than 5,000/mm^3 circulating lymphocytes - No cytopenias, defined as any of the following: - Platelet count less than 100,000/mm^3 - Hemoglobin less than 10 g/dL - Absolute neutrophil count less than 1,500/mm^3 - At least 1 objective measurable disease parameter - Abnormal PET scans will not constitute evaluable disease unless verified by CT scan or other appropriate imaging PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 Life expectancy - Not specified Hematopoietic - See Disease Characteristics - Absolute neutrophil count at least 1,500/mm^3* - Hemoglobin at least 10 g/dL* - Platelet count at least 100,000/mm^3* NOTE: *Without growth factor and/or transfusion support Hepatic - Bilirubin no greater than 2 times upper limit of normal (ULN) OR direct bilirubin normal for patients with Gilbert's Syndrome - AST/ALT no greater than 5 times ULN - Hepatitis B surface antigen negative Renal - Creatinine no greater than 2 times ULN Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative - No uncontrolled active infection - Afebrile for at least 48 hours off antibiotics - No other malignancy within the past 2 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy - See Radiotherapy - No prior immunotherapy for lymphoma Chemotherapy - No prior chemotherapy for lymphoma - No concurrent chemotherapy Endocrine therapy - Not specified Radiotherapy - No prior radiotherapy for lymphoma - No concurrent radiotherapy - No concurrent radioimmunotherapy Surgery - Not specified

Additional Information

Official title Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens For Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Description OBJECTIVES: Primary - Compare the time to rituximab failure in patients with low tumor burden indolent non-Hodgkin's lymphoma treated with rituximab scheduled vs rituximab retreatment. Secondary - Compare the time to first cytotoxic therapy in patients treated with these regimens. - Determine the rationale for beginning cytotoxic therapy, defined as chemotherapy, radiotherapy, or radioimmunotherapy, in patients treated with these regimens. - Compare the toxic effects associated with these regimens in these patients. - Correlate response and duration of response in these patients with rituximab pharmacokinetics. - Compare the health-related quality of life, distress, psychological functioning, physical well-being, and functional well-being of patients treated with these regimens. - Compare the impact of differential treatment response (delayed time to rituximab failure and/or time to first cytotoxic therapy) on quality of life, distress, and psychological functioning in patients treated with these regimens. - Determine, prospectively, the physical and functional well-being of patients during treatment with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to histologic subtype (follicular vs other), age (under 60 vs 60 and over), and the time from diagnosis (less than 1 year vs at least 1 year). - Induction rituximab: Patients receive rituximab IV once a week for 4 weeks. Patients are re-evaluated 9 weeks after the completion of induction rituximab. Patients with a partial or complete response to induction rituximab are randomized to 1 of 2 treatment arms. - Arm I (retreatment rituximab): Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. - Arm II (scheduled rituximab): Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Quality of life is assessed after induction rituximab treatment and at 26, 39, 65, 117, 169, and 221 weeks after randomization. Patients are followed at least annually for 15 years from study entry. PROJECTED ACCRUAL: A total of 389 patients will be accrued for this study within 45 months.
Trial information was received from ClinicalTrials.gov and was last updated in February 2014.
Information provided to ClinicalTrials.gov by Eastern Cooperative Oncology Group.